The second Geneva Consensus: Recommendations for novel live TB vaccines.

[1]  B. Haynes,et al.  Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. , 2009, Vaccine.

[2]  M. Brennan.  The US Food and Drug Administration Provides a Pathway for Licensing Vaccines for Global Diseases , 2009, PLoS medicine.

[3]  M. Brennan,et al.  Tuberculosis vaccine research: the impact of immunology. , 2009, Current opinion in immunology.

[4]  W. Jacobs,et al.  Development of a Murine Mycobacterial Growth Inhibition Assay for Evaluating Vaccines against Mycobacterium tuberculosis , 2009, Clinical and Vaccine Immunology.

[5]  T. Ottenhoff,et al.  Analysis of Mycobacterium tuberculosis-Specific CD8 T-Cells in Patients with Active Tuberculosis and in Individuals with Latent Infection , 2009, PloS one.

[6]  P. Andersen,et al.  TB vaccines: current status and future perspectives , 2009, Immunology and cell biology.

[7]  B. Gicquel,et al.  Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant. , 2009, Vaccine.

[8]  A. Thomas,et al.  MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques , 2009, PloS one.

[9]  Richard Smith.  Eradication of tuberculosis by 2050 impossible without new vaccine , 2009, BMJ : British Medical Journal.

[10]  H. McShane.  Vaccine strategies against tuberculosis. , 2009, Swiss medical weekly.

[11]  B. Zhu,et al.  BCG Vaccines: Their mechanisms of attenuation and impact on safety and protective efficacy , 2009, Human vaccines.

[12]  B. Eley,et al.  BCG vaccination in South African HIV-exposed infants--risks and benefits. , 2009, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[13]  G. Kaplan,et al.  A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. , 2008, The Journal of infectious diseases.

[14]  M. Hatherill,et al.  Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial , 2008, BMJ : British Medical Journal.

[15]  I. Smith,et al.  PhoP, a key player in Mycobacterium tuberculosis virulence. , 2008, Trends in microbiology.

[16]  Serge Mostowy,et al.  PhoP: A Missing Piece in the Intricate Puzzle of Mycobacterium tuberculosis Virulence , 2008, PloS one.

[17]  G. Gao,et al.  Novel genome polymorphisms in BCG vaccine strains and impact on efficacy , 2008, BMC Genomics.

[18]  S. E. Jensen,et al.  Development and validation of an ATP method for rapid estimation of viable units in lyophilised BCG Danish 1331 vaccine. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[19]  Niels Brimnes.  BCG vaccination and WHO's global strategy for tuberculosis control 1948-1983. , 2008, Social science & medicine.

[20]  S. E. Jensen,et al.  Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine. , 2008, Vaccine.

[21]  H. Dockrell,et al.  Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel Recommendations , 2008, PLoS medicine.

[22]  B. Gicquel,et al.  Live tuberculosis vaccines based on phoP mutants: a step towards clinical trials , 2008 .

[23]  M. Brennan,et al.  Development of New Tuberculosis Vaccines: A Global Perspective on Regulatory Issues , 2007, PLoS medicine.

[24]  Julian Parkhill,et al.  Genome plasticity of BCG and impact on vaccine efficacy , 2007, Proceedings of the National Academy of Sciences.

[25]  Bing Chen,et al.  Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. , 2006, Vaccine.

[26]  E. Gormley,et al.  The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. , 2006, Vaccine.

[27]  M. Horwitz,et al.  A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. , 2006, Vaccine.

[28]  M. Horwitz,et al.  Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity. , 2006, Vaccine.

[29]  C. Bonah.  The 'experimental stable' of the BCG vaccine: safety, efficacy, proof, and standards, 1921-1933. , 2005, Studies in history and philosophy of biological and biomedical sciences.

[30]  S. Kaufmann,et al.  Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. , 2005, The Journal of clinical investigation.

[31]  R. Brosch,et al.  Ancient Origin and Gene Mosaicism of the Progenitor of Mycobacterium tuberculosis , 2005, PLoS pathogens.

[32]  S. Cole,et al.  Tuberculosis: from genome to vaccine , 2005, Expert review of vaccines.

[33]  R. Harman.  Development and Control of Medicines and Medical Devices , 2005 .

[34]  M. Brennan,et al.  New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. , 2005, Vaccine.

[35]  M. Horwitz.  Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. , 2005, Microbes and infection.

[36]  W. Jacobs,et al.  Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. , 2005, Microbes and infection.

[37]  Bing Chen,et al.  Long-Term Protection against Tuberculosis following Vaccination with a Severely Attenuated Double Lysine and Pantothenate Auxotroph of Mycobacterium tuberculosis , 2005, Infection and Immunity.

[38]  M. Horwitz,et al.  A New Vaccine against Tuberculosis Affords Greater Survival after Challenge than the Current Vaccine in the Guinea Pig Model of Pulmonary Tuberculosis , 2003, Infection and Immunity.

[39]  Bing Chen,et al.  A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis , 2002, Nature Medicine.

[40]  C. Buchrieser,et al.  A new evolutionary scenario for the Mycobacterium tuberculosis complex , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. Kaufmann,et al.  Cell-Mediated Immunity Induced by Recombinant Mycobacterium bovis Bacille Calmette-Guérin Strains Against an Intracellular Bacterial Pathogen: Importance of Antigen Secretion or Membrane-Targeted Antigen Display as Lipoprotein for Vaccine Efficacy1 , 2002, The Journal of Immunology.

[42]  WMADo Helsinki.  World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. , 2000, Nursing ethics.

[43]  H. Dockrell,et al.  Human CD8+ T Cells Specific forMycobacterium tuberculosis Secreted Antigens in Tuberculosis Patients and Healthy BCG-Vaccinated Controls in The Gambia , 2000, Infection and Immunity.

[44]  P. Andersen,et al.  Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells , 2000, European journal of immunology.

[45]  A. Sette,et al.  Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[46]  D. Smith,et al.  Animal models for experimental tuberculosis. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  C. Buchrieser,et al.  Comparative Genomics Uncovers Large Tandem Chromosomal Duplications in Mycobacterium Bovis BCG Pasteur , 2000, Yeast.

[48]  G. Schoolnik,et al.  Comparative genomics of BCG vaccines by whole-genome DNA microarray. , 1999, Science.

[49]  P. Tyler,et al.  Development of a tetrazolium salt assay for rapid determination of viability of BCG vaccines. , 1999, Vaccine.

[50]  M. Behr,et al.  A historical and molecular phylogeny of BCG strains. , 1999, Vaccine.

[51]  Mic N. Hamers,et al.  Multiuse Biopharmaceutical Manufacturing , 1993, Bio/Technology.

[52]  J. Flynn,et al.  Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Chen Zr,et al.  Experimental research on utilization of bioluminescent technique to substitute the current viability count for BCG vaccine. , 1989 .

[54]  P. Sparrow.  GM Risk Assessment. , 2009, Methods in molecular biology.

[55]  C. Soto,et al.  Intracellular replication of attenuated Mycobacterium tuberculosis phoP mutant in the absence of host cell cytotoxicity. , 2009, Microbes and infection.

[56]  Bo Qing.  International ethical guidelines for biomedical research involving human subjects , 2003 .

[57]  M. Shaughnessy.  Protection of human subjects. , 1980, JAMA.